3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 43.40 (-0.06), BIIB: 325.13 (-10.67), AMGN: 159.44 (-0.16)
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
ABT: 43.40 (-0.06), BIIB: 325.13 (-10.67), VRX: 136.92 (-1.24), BMY: 57.69 (-0.86)
RBCC 3D Bioprinting Partner Awarded Prestigious Grant
Business Wire - Thu Jul 31, 5:54AM CDT
The joint venture of Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D), moved significantly closer to its funding goals this week thanks to a prestigious research grant from the National Institutes of Health.
ABT: 43.40 (-0.06), AMGN: 159.44 (-0.16)
RBCC Developing New Tech to Help Prevent Deaths From Prescription Overdoses
Business Wire - Wed Jul 02, 4:00AM CDT
Work continues on a new injectable, sustained-release technology that Rainbow Coral Corp. (OTCBB: RBCC) hopes can help prevent a deadly epidemic of prescription narcotic overdoses.
ABT: 43.40 (-0.06), BIIB: 325.13 (-10.67), VRX: 136.92 (-1.24), BMY: 57.69 (-0.86)
RBCC: New Research Could Massively Expand Market for Addiction Therapy Technology
Business Wire - Thu Jun 26, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) works to deliver a new injectable, sustained-release technology poised to vastly improve patients' use of Naltrexone, new research into the drug's potential could soon dramatically expand the drug's market and usage.
RBCC: New Innovations Spur Demand for 3D Printing in Medicine
Business Wire - Thu Feb 20, 4:00AM CST
As Rainbow Coral Corp. (OTCBB: RBCC) works to market and develop an innovative new 3D bioprinting system, new 3D printing innovations are generating massive new demand for the technology from patients and doctors alike in the medical industry.
New Product Puts RBCC on Leading Edge of Organ Regeneration Research
Business Wire - Tue Feb 18, 4:00AM CST
The 3D printing of functional human organs could be a reality within the next decade, and Rainbow Coral Corp. (OTCBB: RBCC) is helping to lead the bioprinting revolution now underway.
RBCC Seeks Out Capital Partners for 3D Bioprinting Expansion
Business Wire - Thu Feb 06, 4:00AM CST
Rainbow Bioscience, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC), announced today that it is seeking out new capital partners to help expand marketing and streamline development on the BiO Assay, a 3D bioprinting system poised to potentially revolutionize the drug development industry.
CVBF: 15.23 (+0.12)